Marinus Pharmaceuticals Inc (NASDAQ: MRNS) is -87.30% lower on its value in year-to-date trading and has touched a low of $1.11 and a high of $11.26 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The MRNS stock was last observed hovering at around $1.41 in the last trading session, with the day’s loss setting it -0.03%.
Currently trading at $1.38, the stock is -80.55% and -83.89% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.59 million and changing -2.13% at the moment leaves the stock -83.44% off its SMA200. MRNS registered -82.92% loss for a year compared to 6-month gain of -79.71%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -84.73% loss in the last 1 month and extending the period to 3 months gives it a -85.64%, and is -81.65% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 36.26% over the week and 13.52% over the month.
Marinus Pharmaceuticals Inc (MRNS) has around 165 employees, a market worth around $75.40M and $30.99M in sales. Profit margin for the company is -456.31%. Distance from 52-week low is 24.32% and -87.74% from its 52-week high. The company has generated returns on investments over the last 12 months (-125.60%).
Marinus Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at -$0.66 with sales reaching $9.12M over the same period.The EPS is expected to grow by 16.53% this year, but quarterly earnings will post 31.80% year-over-year. Quarterly sales are estimated to shrink -12.10% in year-over-year returns.
Marinus Pharmaceuticals Inc (MRNS) Top Institutional Holders
The shares outstanding are 54.58M, and float is at 50.81M with Short Float at 6.84%.
Marinus Pharmaceuticals Inc (MRNS) Insider Activity
The most recent transaction is an insider sale by Shafer Christina,the company’sCHIEF COMMERCIAL OFFICER. SEC filings show that Shafer Christina sold 2,153 shares of the company’s common stock on Feb 20 ’24 at a price of $9.56 per share for a total of $20583.0. Following the sale, the insider now owns 60308.0 shares.
Marinus Pharmaceuticals Inc disclosed in a document filed with the SEC on Feb 20 ’24 that MANNING MARTHA E (SVP, GEN. COUNSEL & CORP. SEC.) sold a total of 1,894 shares of the company’s common stock. The trade occurred on Feb 20 ’24 and was made at $9.57 per share for $18126.0. Following the transaction, the insider now directly holds 52966.0 shares of the MRNS stock.
Still, SEC filings show that on Feb 16 ’24, Braunstein Scott (CHAIRMAN AND CEO) disposed off 11,850 shares at an average price of $9.94 for $0.12 million. The insider now directly holds 223,512 shares of Marinus Pharmaceuticals Inc (MRNS).
